Biotechnology (538) | Intellectual Property (538)

Browse by Subcategory

License Agreements (536)
Trademark Agreements (2)

Browse by Company

89bio, Inc. (1)
ABEONA THERAPEUTICS INC. (2)
ADURO BIOTECH, INC. (2)
Adverum Biotechnologies, Inc. (2)
Aeglea BioTherapeutics, Inc. (2)
AGENUS INC (3)
AGIOS PHARMACEUTICALS INC (2)
Aimmune Therapeutics, Inc. (1)
AKCEA THERAPEUTICS, INC. (1)
Akebia Therapeutics, Inc. (2)
Aldeyra Therapeutics, Inc. (1)
Allogene Therapeutics, Inc. (1)
ALNYLAM PHARMACEUTICALS, INC. (1)
ALPINE IMMUNE SCIENCES, INC. (2)
Altimmune, Inc. (5)
Anixa Biosciences Inc (3)
Annovis Bio, Inc. (3)
Applied Therapeutics Inc. (1)
AQUINOX PHARMACEUTICALS, INC (2)
Arbutus Biopharma Corp (3)
Arcus Biosciences, Inc. (2)
Arcutis Biotherapeutics, Inc. (3)
ARENA PHARMACEUTICALS INC (1)
Aridis Pharmaceuticals, Inc. (3)
ARROWHEAD PHARMACEUTICALS, INC. (2)
Arsanis, Inc. (9)
ARYA Sciences Acquisition Corp II (1)
ASSEMBLY BIOSCIENCES, INC. (2)
Atara Biotherapeutics, Inc. (4)
Athenex, Inc. (10)
AVEO PHARMACEUTICALS INC (3)
AVROBIO, Inc. (2)
Axovant Sciences Ltd. (1)
Ayala Pharmaceuticals, Inc. (3)
AzurRx BioPharma, Inc. (2)
Beam Therapeutics Inc. (8)
BELLICUM PHARMACEUTICALS, INC (4)
BICYCLE THERAPEUTICS Ltd (1)
BIOSPECIFICS TECHNOLOGIES CORP (1)
BIOXYTRAN, INC (1)
bluebird bio, Inc. (2)
Blueprint Medicines Corp (1)
Bone Biologics Corp (2)
BridgeBio Pharma, Inc. (6)
Cabaletta Bio, Inc. (2)
CAPRICOR THERAPEUTICS, INC. (1)
CASI Pharmaceuticals, Inc. (6)
CASTLE BIOSCIENCES INC (1)
CATALYST BIOSCIENCES, INC. (1)
CATALYST PHARMACEUTICALS, INC. (2)
Cellular Biomedicine Group, Inc. (2)
Chardan Healthcare Acquisition Corp. (4)
CHIMERIX INC (2)
Coherus BioSciences, Inc. (2)
Corvus Pharmaceuticals, Inc. (1)
Cue Biopharma, Inc. (2)
CURIS INC (1)
Cyclerion Therapeutics, Inc. (1)
CytoDyn Inc. (1)
CytomX Therapeutics, Inc. (1)
CYTORI THERAPEUTICS, INC. (1)
Deciphera Pharmaceuticals, Inc. (1)
Dicerna Pharmaceuticals Inc (1)
Eagle Pharmaceuticals, Inc. (1)
Editas Medicine, Inc. (1)
Eidos Therapeutics, Inc. (1)
Eiger BioPharmaceuticals, Inc. (5)
Emerald Bioscience, Inc. (2)
Emergent BioSolutions Inc. (1)
Enochian Biosciences Inc (2)
Evelo Biosciences, Inc. (1)
EXACT SCIENCES CORP (2)
EXICURE, INC. (7)
FATE THERAPEUTICS INC (5)
FIBROGEN INC (2)
FIVE PRIME THERAPEUTICS INC (4)
Flex Pharma, Inc. (2)
Frequency Therapeutics, Inc. (2)
Gemphire Therapeutics Inc. (1)
Generation Bio Co. (3)
GENOCEA BIOSCIENCES, INC. (1)
Genprex, Inc. (3)
GeoVax Labs, Inc. (2)
Gilead Sciences (1)
Global Blood Therapeutics, Inc. (1)
Gossamer Bio, Inc. (1)
GTX INC (14)
Harpoon Therapeutics, Inc. (1)
Health Sciences Acquisitions Corp (2)
HEAT BIOLOGICS, INC. (5)
HedgePath Pharmaceuticals, Inc. (1)
HISTOGENICS CORP (4)
HUMANIGEN, INC (1)
iBio, Inc. (3)
IDEAYA Biosciences, Inc. (4)
Immune Therapeutics, Inc. (5)
IMMUNOMEDICS INC (1)
Incyte (1)
INFINITY PHARMACEUTICALS, INC. (1)
Inmune Bio, Inc. (1)
Innovation Pharmaceuticals Inc. (1)
INSMED Inc (2)
Intellia Therapeutics, Inc. (3)
IONIS PHARMACEUTICALS INC (1)
IRONWOOD PHARMACEUTICALS INC (2)
Jounce Therapeutics, Inc. (2)
Kadmon Holdings, Inc. (2)
Karuna Therapeutics, Inc. (2)
Karyopharm Therapeutics Inc. (1)
Keros Therapeutics, Inc. (1)
Kiniksa Pharmaceuticals, Ltd. (2)
Kura Oncology, Inc. (3)
LA JOLLA PHARMACEUTICAL CO (1)
Lantern Pharma Inc. (6)
LEAP THERAPEUTICS, INC. (1)
LifeSci Acquisition Corp. (1)
Ligand Pharmaceuticals Incorporated (2)
LogicBio Therapeutics, Inc. (3)
MACROGENICS INC (4)
Magenta Therapeutics, Inc. (2)
MANHATTAN SCIENTIFICS INC (1)
Marker Therapeutics, Inc. (1)
MATEON THERAPEUTICS INC (2)
MEI Pharma, Inc. (2)
MeiraGTx Holdings plc (5)
Mersana Therapeutics, Inc. (2)
Millendo Therapeutics, Inc. (1)
MIRAGEN THERAPEUTICS, INC. (3)
Mirum Pharmaceuticals, Inc. (7)
Moleculin Biotech, Inc. (1)
Monopar Therapeutics (8)
Myovant Sciences Ltd. (1)
NANOVIRICIDES, INC. (1)
NantKwest, Inc. (4)
Neuralstem, Inc. (2)
NEUROCRINE BIOSCIENCES INC (1)
NEWLINK GENETICS CORP (7)
NextCure, Inc. (2)
Ohr Pharmaceutical Inc (1)
OncoCyte Corp (1)
ONCOSEC MEDICAL Inc (1)
Ophthotech Corp. (3)
Opko Health, Inc. (1)
ORAGENICS INC (1)
Orchard Therapeutics plc (1)
ORGANOVO HOLDINGS, INC. (1)
Oyster Point Pharma, Inc. (1)
Pfenex Inc. (8)
PhaseBio Pharmaceuticals Inc (3)
PRECISION BIOSCIENCES INC (6)
PREMIER BIOMEDICAL INC (1)
Prevail Therapeutics Inc. (2)
PROTEON THERAPEUTICS INC (3)
PROTEOSTASIS THERAPEUTICS, INC. (3)
Prothena Corp plc (3)
PTC THERAPEUTICS, INC. (2)
PUMA BIOTECHNOLOGY, INC. (7)
Qrons Inc. (2)
Radius Health, Inc. (1)
Regeneron Pharmaceuticals (3)
REGENERX BIOPHARMACEUTICALS INC (2)
REGENXBIO Inc. (4)
Retrophin, Inc. (2)
Rezolute, Inc. (3)
RIGEL PHARMACEUTICALS INC (1)
RITTER PHARMACEUTICALS INC (2)
ROCKET PHARMACEUTICALS, INC. (1)
Rubius Therapeutics, Inc. (1)
Sarepta Therapeutics, Inc. (1)
SEATTLE GENETICS INC (1)
SELECTA BIOSCIENCES INC (4)
SELLAS Life Sciences Group, Inc. (2)
Sesen Bio, Inc. (1)
Sierra Oncology, Inc. (1)
Solid Biosciences Inc. (2)
Sorrento Therapeutics, Inc. (5)
Spero Therapeutics, Inc. (2)
SPHERIX INC (2)
SpringWorks Therapeutics, Inc. (2)
Stellar Biotechnologies, Inc. (7)
Stoke Therapeutics, Inc. (4)
Sun BioPharma, Inc. (2)
SUNESIS PHARMACEUTICALS INC (1)
Surface Oncology, Inc. (2)
Syndax Pharmaceuticals Inc (2)
Syros Pharmaceuticals, Inc. (2)
TENAX THERAPEUTICS, INC. (1)
Tocagen Inc (1)
Tonix Pharmaceuticals Holding Corp. (6)
Tracon Pharmaceuticals, Inc. (1)
Translate Bio, Inc. (1)
Turning Point Therapeutics, Inc. (3)
Ultragenyx Pharmaceutical Inc. (3)
United Therapeutics Corp (1)
Unity Biotechnology, Inc. (14)
UroGen Pharma Ltd. (1)
Vaxcyte, Inc. (1)
Verastem, Inc. (1)
Vericel Corp (1)
VICAL INC (7)
Viela Bio, Inc. (2)
Vir Biotechnology, Inc. (14)
VITAL THERAPIES INC (1)
Voyager Therapeutics, Inc. (2)
vTv Therapeutics Inc. (2)
XBiotech Inc. (1)
Xencor Inc (3)
XOMA Corp (4)
Y-mAbs Therapeutics, Inc. (3)
ZAFGEN, INC. (5)
Zai Lab Ltd (4)
Zentalis Pharmaceuticals, LLC (2)
ZIOPHARM ONCOLOGY INC (4)

Recent Contracts

License and Development Agreement for CB-5339 by and between Cleave Therapeutics, Inc. and CASI Pharmaceuticals, Inc. dated March 5, 2021 (CASI Pharmaceuticals, Inc., Filed With SEC on May 13, 2021)
License and Supply Agreement, dated March 21, 2021, by and between the Registrant and Immedica Pharma AB (Aeglea BioTherapeutics, Inc., Filed With SEC on May 10, 2021)
License Agreement, dated April 14, 2021, between the Company and OyaGen, Inc (Tonix Pharmaceuticals Holding Corp., Filed With SEC on May 10, 2021)
License Agreement between Turning Point Therapeutics, Inc. and Zai Lab (Shanghai) Co., Ltd. dated January 10, 2021 (Zai Lab Ltd, Filed With SEC on May 10, 2021)
Amendment No. 1 to License Agreement between Turning Point Therapeutics, Inc. and Zai Lab (Shanghai) Co., Ltd. dated March 31, 2021 (Zai Lab Ltd, Filed With SEC on May 10, 2021)
Second Amendment to License Agreement dated as of February 15, 2021 by and between Athenex, Inc. and PharmaEssentia Corp (Athenex, Inc., Filed With SEC on May 6, 2021)
Amendment No. 3 to the License Agreement, dated February 24, 2021, by and between the Company and Pierre Fabre Medicament SAS (PUMA BIOTECHNOLOGY, INC., Filed With SEC on May 6, 2021)
Third Amendment to Exclusive License Agreement between the Company and The Rockefeller University, dated March 1, 2021 (Vir Biotechnology, Inc., Filed With SEC on May 6, 2021)
Amendment No. 1, dated March 18, 2021 to License Agreement, dated as of August 20, 2015 between Registrant and Memorial Sloan Kettering Cancer Center (Y-mAbs Therapeutics, Inc., Filed With SEC on May 6, 2021)
Amendments Nos. 1 and 2 to the License Agreement, dated September 25, 2017, by and between Kiniksa Pharmaceuticals and Regeneron Pharmaceuticals, Inc (Kiniksa Pharmaceuticals, Ltd., Filed With SEC on May 6, 2021)